POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS

• US 20110052501A1
• Filed: 02/01/2009
• Published: 03/03/2011
• Est. Priority Date: 01/31/2008
• Status: Abandoned Application

• Current Assignee: Compugen Ltd
• Original Assignee: Compugen Ltd
• Inventors: Sameach-Greenwald, Shirley, Kinar, Yaron, Montia, Eve, Dassa, Liat, Rotman, Galit, Cohen-Dayag, Anat, Rosenberg, Avi Yeshah, Walach, Shira, Toporik, Amir, Nemzar, Sergey, Levy, Ofer, Levine, Zurit
• Application Number:
  US12/863,189
• Publication Number:
  US 20110052501A1
• Time in Patent Office: Days
• US Class Current: 424/9.2
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 16/2887 against CD20
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagnostic and therapeutic usages. This invention further relates to the discovery of extracellular domains of KIAA0746 and its variants, CD20 and its variants, CD55 and its variants, which are suitable targets for immunotherapy, cancer therapy, treatment of inflammatory, allergic and autoimmune disorders, and drug development.

Claims

1-165. -165. (canceled)

166. An isolated polypeptide having an amino acid sequence as set forth in HUMDAF_P30 (SEQ ID NO:

56), or a fragment or variant thereof that possesses at least 95% sequence identity therewith.

167. The polypeptide of claim 166, wherein said fragment comprises an ectodomain of SEQ ID NO:

56.

169. The polypeptide of claim 166, comprising the amino acid sequence as set forth in SEQ ID NO:

70 or an immunogenic fragment thereof.

170. The polypeptide of claim 166, comprising an amino acid sequence having at least 80% homology to the sequence as that set forth in SEQ ID NO:

196, or an immunogenic fragment thereof.

168. An isolated polypeptide having an amino acid sequence as set forth in SEQ ID NO:

108, or a conjugate thereof.

171. A monoclonal or polyclonal antibody or an antigen binding fragment thereof comprising an antigen binding site that binds specifically to any one of SEQ ID NOs:

56, 108, 70, 196.

172. A pharmaceutical composition, comprising the antibody of claim 171 in a pharmaceutically acceptable carrier, adapted for treatment or prevention of disorder selected from cancer and immune related conditions.

173. The pharmaceutical composition of claim 172, wherein the antibody comprises an antigen binding site that binds specifically to any one of SEQ ID NOs:

56, 108, 70, wherein the cancer is selected from the group consisting of tumors of breast, prostate, lung, colon, colorectal, ovary, spleen, kidney, bladder, head and neck, uterus, testicles, stomach, gastric, cervix, liver, bone, skin, pancreas, brain, and hematological malignancies such as acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, multiple myeloma, Hodgkin'"'"'s lymphoma, Non-Hodgkin'"'"'s lymphoma, and wherein the cancer is non-metastatic, invasive or metastatic.

174. The pharmaceutical composition of claim 172, wherein said antibody comprises an antigen binding site that binds specifically to SEQ ID NO:

196, wherein the cancer is selected from the group consisting of tumors of breast, prostate, colon, colorectal, ovary, spleen, kidney, bladder, head and neck, uterus, testicles, stomach, gastric, cervix, liver, bone, skin, pancreas, brain, and wherein the cancer is non-metastatic, invasive or metastatic.

175. The pharmaceutical composition of claim 172, wherein said antibody comprises an antigen binding site that binds specifically to any one of SEQ ID NOs:

56, 108, 70, and wherein the immune related condition is selected from the group consisting of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), lupus nephtirits and multiple sclerosis (MS), inflammatory bowel disease (IBD), ulcerative colitis, psoriasis, acute and chronic rejection of organ transplantation and of allogeneic stem cell transplantation, autologous stem cell transplantation, bone marrow transplantation, treatment of Graft Versus Host Disease (GVHD), rejection in xenotransplantation, and disease states in which complement activation and deposition is involved in pathogenesis.

176. The pharmaceutical composition of claim 172, wherein said antibody comprises an antigen binding site that binds specifically to SEQ ID NO:

196, and wherein the immune related condition is selected from the group consisting of systemic lupus erythematosus (SLE), lupus nephtirits and multiple sclerosis (MS), inflammatory bowel disease (IBD), ulcerative colitis, psoriasis, acute and chronic rejection of allogeneic stem cell transplantation, autologous stem cell transplantation, bone marrow transplantation, treatment of Graft Versus Host Disease (GVHD), rejection in xenotransplantation, and disease states in which complement activation and deposition is involved in pathogenesis.

177. The antibody or fragment according to claim 171, wherein the antibody is a fully human antibody, a chimeric antibody, a humanized or primatized antibody.

178. The antibody or fragment according to claim 171, wherein the antibody is selected from the group consisting of Fab, Fab′

, F(ab′

)₂, F(ab′

), F(ab), Fv or scFv fragment and minimal recognition unit.

179. The antibody or fragment according to claim 171, wherein the antibody is coupled to a detectable marker, selected from any one of radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound or a chemiluminescent compound, or to an effector moiety, selected from any one of an enzyme, a toxin, a therapeutic agent, or a chemotherapeutic agent.

180. A method of treating or preventing a disorder selected from any one of cancer and immune related condition in a patient, comprising administering to the patient an effective amount of the antibody or fragment according to claim 171 or the pharmaceutical composition according to claim 172.

181. The method of claim 180, used in combination therapy with other treatment methods known in the art selected from the group consisting of radiation therapy, antibody therapy, chemotherapy, surgery, or in combination therapy with conventional drugs, anti-cancer agents, immunosuppressants, cytotoxic drugs for cancer, chemotherapeutic agents, or in combination with therapeutic agents targeting other complement regulatory proteins (CRPs), or wherein the treatment is combined with a moiety useful for treating immune related conditions, selected from any one of a cytokine antibody, cytokine receptor antibody, drug, or another immunomodulatory agent.

182. The method of claim 180, wherein the cancer is selected from the group consisting of and tumors of breast, prostate, lung, colon, colorectal, ovary, spleen, kidney, bladder, head and neck, uterus, testicles, stomach, gastric, cervix, liver, bone, skin, pancreas, brain, and hematological malignancies such as acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, multiple myeloma, Hodgkin'"'"'s lymphoma, Non-Hodgkin'"'"'s lymphoma, and wherein the cancer is non-metastatic, invasive or metastatic.

183. The method of claim 180, wherein the immune related condition is selected from the group consisting of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), lupus nephtirits and multiple sclerosis (MS), inflammatory bowel disease (IBD), ulcerative colitis, psoriasis, acute and chronic rejection of organ transplantation and of allogeneic stem cell transplantation, autologous stem cell transplantation, bone marrow transplantation, treatment of Graft Versus Host Disease (GVHD), rejection in xenotransplantation, and disease states in which complement activation and deposition is involved in pathogenesis.

184. An assay for detecting the presence of polypeptide comprising the amino acid sequence as set forth in any one of SEQ ID NOs:

56, 108, 70, 196, or a fragment or variant thereof in a biological sample comprising contacting the sample with an antibody specific to any one of SEQ ID NOs;

56, 108, 70, 196, and detecting the specific binding of said antibody to any one of SEQ ID NOs;

56, 108, 70, 196, or a fragment or variant thereof in the sample.

192. The method of claim 184 wherein the detection is conducted by immunoassay.

185. A method for any one of screening for a disease, detecting a presence or a severity of a disease, diagnosing a disease, prognosis of a disease, monitoring disease progression or treatment efficacy or relapse of a disease, or selecting a therapy for a disease, comprising detecting in a subject or in a sample obtained from the subject a polypeptide having a sequence at least 95% homologous to an amino acid sequence selected from those set forth in any one of SEQ ID NOs:

56, 108, 70, 196.

186. The method of claim 185, wherein detecting the polypeptide is performed in vivo or in vitro.

187. The method of claim 186 wherein the disease is selected from any one of cancer and immune related condition.

188. The method of claim 187, comprising detecting in a subject or in a sample obtained from the subject a polypeptide having a sequence at least 95% homologous to an amino acid sequence selected from those set forth in any one of SEQ ID NOs:

56, 108, 70, wherein the cancer is selected from the group consisting of tumors of breast, prostate, lung, colon, colorectal, ovary, spleen, kidney, bladder, head and neck, uterus, testicles, stomach, gastric, cervix, liver, bone, skin, pancreas, brain, and hematological malignancies such as acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, multiple myeloma, Hodgkin'"'"'s lymphoma, Non-Hodgkin'"'"'s lymphoma, and wherein the cancer is non-metastatic, invasive or metastatic.

189. The method of claim 187, comprising detecting in a subject or in a sample obtained from the subject a polypeptide having a sequence at least 95% homologous to an amino acid sequence set forth in SEQ ID NO:

196, wherein the cancer is selected from the group consisting of tumors of breast, prostate, colon, colorectal, ovary, spleen, kidney, bladder, head and neck, uterus, testicles, stomach, gastric, cervix, liver, bone, skin, pancreas, brain, and wherein the cancer is non-metastatic, invasive or metastatic.

190. The method of claim 186, comprising detecting in a subject or in a sample obtained from the subject a polypeptide having a sequence at least 95% homologous to an amino acid sequence selected from those set forth in any one of SEQ ID NOs:

56, 108, 70, wherein the immune related condition is selected from the group consisting of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), lupus nephtirits and multiple sclerosis (MS), inflammatory bowel disease (IBD), ulcerative colitis, psoriasis, acute and chronic rejection of organ transplantation and of allogeneic stem cell transplantation, autologous stem cell transplantation, bone marrow transplantation, treatment of Graft Versus Host Disease (GVHD), rejection in xenotransplantation, and disease states in which complement activation and deposition is involved in pathogenesis.

191. The method of claim 186, comprising detecting in a subject or in a sample obtained from the subject a polypeptide having a sequence at least 95% homologous to an amino acid sequence set forth in SEQ ID NO:

196, wherein the immune related condition is selected from the group consisting of, systemic lupus erythematosus (SLE), lupus nephtirits and multiple sclerosis (MS), inflammatory bowel disease (IBD), ulcerative colitis, psoriasis, acute and chronic rejection of allogeneic stem cell transplantation, autologous stem cell transplantation, bone marrow transplantation, treatment of Graft Versus Host Disease (GVHD), rejection in xenotransplantation, and disease states in which complement activation and deposition is involved in pathogenesis.